Log In
BCIQ
Print this Print this
 

OpRegen

  Manage Alerts
Collapse Summary General Information
Company Cell Cure Neurosciences Ltd.
DescriptionHuman embryonic stem cell-derived retinal pigmented epithelial (RPE) cells
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentPhase I/II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat dry age-related macular degeneration (AMD); Treat dry age-related macular degeneration (AMD) with geographic atrophy (GA); Treat geographic atrophy (GA) associated with dry or non-neovascular age-related macular degeneration (AMD)
Regulatory Designation U.S. - Fast Track (Treat dry age-related macular degeneration (AMD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$31.0M

$2.0M

$28.0M


 Deals Details
Get a free BioCentury trial today